Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2026-02-18 00:00:00 ET · period of report 2026-02-13 · accession 0000875320-26-000076 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-18 | 2026-02-13 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | F - Tax | $487.76 | -3,804 | 47.6K | -7% | -$1.86M | |
| 2026-02-18 | 2026-02-13 | VRTX | Tatsis Ourania | EVP, Chief Reg, Quality Off | S - Sale | $499.99 | -1,500 | 46.1K | -3% | -$750.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-13 | F | D | 3,804 | $487.76 | 47,632 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-13 | S | D | 1,500 | $499.99 | 46,132 | D | — | — | (F3) Dr. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F2) Open market sales reported on this line occurred at a weighted average price of $499.99 (range $499.99 to $500.04). |